{
    "id": 5163,
    "fullName": "SETD2 mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "SETD2 mutant indicates an unspecified mutation in the SETD2 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 29072,
        "geneSymbol": "SETD2",
        "terms": [
            "SETD2",
            "HBP231",
            "HIF-1",
            "HIP-1",
            "HSPC069",
            "HYPB",
            "KMT3A",
            "LLS",
            "p231HBP",
            "SET2"
        ]
    },
    "variant": "mutant",
    "createDate": "04/22/2015",
    "updateDate": "07/28/2015",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2067,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a rapamycin-resistant human kidney cancer cell line harboring mutations in CDKN2A, SETD2 and VHL demonstrated sensitivity and inhibition of MTORC1 signaling when treated with Sapanisertib (MLN0128) (PMID: 25261369).",
            "molecularProfile": {
                "id": 4976,
                "profileName": "CDKN2A mut SETD2 mut VHL mut"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2380,
                    "pubMedId": 25261369,
                    "title": "Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25261369"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 4975,
            "profileName": "SETD2 mutant",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 4976,
            "profileName": "CDKN2A mut SETD2 mut VHL mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}